| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/21/2002 | US6391858 Gene delivery in various muscle cell types; gene therapy for expression of erythropoietin to treat blood disorders such as anemias, for example |
| 05/21/2002 | US6391857 Methods and compositions for endothelial binding |
| 05/21/2002 | US6391856 Method for treatment of allergic reaction using formyl peptide |
| 05/21/2002 | US6391855 Compounds and methods for modulating junctional adhesion molecule-mediated functions |
| 05/21/2002 | US6391854 Water soluble hypoglycemic agents |
| 05/21/2002 | US6391853 Human tissue inhibitor of metalloproteinase-4 |
| 05/21/2002 | US6391852 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases |
| 05/21/2002 | US6391851 Hydrochlorides of vancomycin antibiotics and process for producing the same |
| 05/21/2002 | US6391850 Methods and compositions for inhibiting angiogenesis |
| 05/21/2002 | US6391849 Method and pharmaceutical composition for disrupting lactation in a mammary gland and for treating and preventing mastitis |
| 05/21/2002 | US6391848 Soybean protein nutraceuticals |
| 05/21/2002 | US6391847 Modulating transcription |
| 05/21/2002 | US6391832 Medical emulsion for lubrication and delivery of drugs |
| 05/21/2002 | US6391651 Materials and methods for detection of insulin dependent diabetes |
| 05/21/2002 | US6391637 Activating genetically engineered cells to generate preferential immunoglobulins; obtain cells, incubate with preferential polypeptides, recover preferential immunoglobulins |
| 05/21/2002 | US6391636 Nucleotide sequences for use in treating cell proliferation defects |
| 05/21/2002 | US6391635 Monoclonal human natural antibodies |
| 05/21/2002 | US6391633 Genetically engineered cells for use as tools in the expression of heterologous genes |
| 05/21/2002 | US6391607 Human DNase I hyperactive variants |
| 05/21/2002 | US6391606 Peptides; for use in the develoment of human diagnostic and therapeutic agents |
| 05/21/2002 | US6391602 Polypeptide for use in the treatment of cardiovascular disorders |
| 05/21/2002 | US6391600 PcrA helicase |
| 05/21/2002 | US6391589 Human chemokine beta-10 mutant polypeptides |
| 05/21/2002 | US6391588 Nucleotides squences coding preferential amino acid sequences for use in treating bone disorder in mammals |
| 05/21/2002 | US6391584 Expression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target proteins |
| 05/21/2002 | US6391581 DNA encoding interleukin-4 receptors |
| 05/21/2002 | US6391580 Ras proteins |
| 05/21/2002 | US6391579 Nucleotide sequences coding transport protein for use in the treatment of thyroid defects |
| 05/21/2002 | US6391571 Mutein which is capable of binding to biotin but has a low affinity for it; for use as interference elimination reagent in analyses |
| 05/21/2002 | US6391567 Identifying compounds inhibiting DC-sign facilitation of HIV into cells |
| 05/21/2002 | US6391565 Methods of detecting growth differentiation factor-3 |
| 05/21/2002 | US6391554 Detecting cancerous conditions by assaying for telomerase activity |
| 05/21/2002 | US6391543 Screening sample for preferential nucleotide sequences; incubate sample with nucleotide sequences, monitor sample for signal indicating bound nucleotide sequences |
| 05/21/2002 | US6391452 Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| 05/21/2002 | US6391336 Inorganic-polymer complexes for the controlled release of compounds including medicinals |
| 05/21/2002 | US6391315 Composition comprising mixed antigens derived from both cell surface extracts and cultured broth, treated by chromatography to obtain effective fraction free of endotoxin and whole cells |
| 05/21/2002 | US6391314 Immunogenic composition comprising vector that contains and expresses in vivo in porcine host cell, nucleic acid molecule or fragment thereof encoding type ii porcine circovirus antigen and pharmaceutically acceptable vehicle or diluent |
| 05/21/2002 | US6391312 Remedies for diabetes |
| 05/21/2002 | US6391311 Polypeptide comprising amino acid sequence at least about 80% identical to specified sequence, which has biological activity of promoting selective growth and/or survival of human umbilical vein endothelial cells in in vitro assay |
| 05/21/2002 | US6391306 Treatment of infectious diseases with hsp90-peptide complexes |
| 05/21/2002 | US6391305 Conjugates useful in the treatment of prostate cancer |
| 05/21/2002 | US6391304 Medicinal product capable of inducing protection in feline host against infection with feline immunodeficiency virus, comprising isolated peptide consisting of or containing specified amino acid sequence |
| 05/21/2002 | US6391301 Agent for identifying and treating metastasizing tumors |
| 05/21/2002 | US6391300 Introducing into extracorporeally circulating blood factor ixa compound which is glu-gly-arg chloromethyl ketone-inactivated human factor ixa |
| 05/21/2002 | US6391299 Anti-factor IX/IXa antibodies |
| 05/21/2002 | US6391298 Method of using PON-1 to decrease atheroma formation |
| 05/21/2002 | US6391297 Differentiation of adipose stromal cells into osteoblasts and uses thereof |
| 05/21/2002 | US6391296 Method of stabilizing useful protein and useful protein compositions |
| 05/21/2002 | US6391285 Antimicrobial polypeptide and methods of use |
| 05/21/2002 | US6391047 Human pregnancy therapy |
| 05/21/2002 | US6390821 Phosphorylation |
| 05/21/2002 | CA2215745C Human stat4 |
| 05/21/2002 | CA2183241C Yeast strains and modified albumins |
| 05/21/2002 | CA2153254C Cloning of enterokinase and method of use |
| 05/21/2002 | CA2148595C Molecule labelling using 2-hydrazinopyridine derivatives |
| 05/21/2002 | CA2119932C Pressurized hydrofluoroalkane pharmaceutical aerosol compositions |
| 05/21/2002 | CA2039706C Method for preparing amino acid derivatives and therapeutical applications of same |
| 05/21/2002 | CA1341359C Manufacturing process for a single-cell lifeform killing or growth inhibiting composition containing fluorine (f-) and lithium (li+) |
| 05/20/2002 | WO2002039947A2 Carrier vectors through an epithelium with tight junctions |
| 05/17/2002 | CA2363147A1 Stable lactase compositions |
| 05/16/2002 | WO2002039121A2 Methods for detecting the efficacy of anticancer treatments |
| 05/16/2002 | WO2002038805A2 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases |
| 05/16/2002 | WO2002038797A2 Modulators of bruton's tyrosine kinase, their identification and use |
| 05/16/2002 | WO2002038795A2 Braf35 protein and brca2/braf35 complex and methods of use |
| 05/16/2002 | WO2002038781A1 Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure |
| 05/16/2002 | WO2002038776A1 Regulation of human fatty acid coa ligase |
| 05/16/2002 | WO2002038775A2 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |
| 05/16/2002 | WO2002038767A2 G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| 05/16/2002 | WO2002038764A2 Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
| 05/16/2002 | WO2002038759A2 Method for inducing apoptiosis |
| 05/16/2002 | WO2002038744A2 Proteases |
| 05/16/2002 | WO2002038743A2 Deaminase catalyzing the removal of the cyclopropyl moiety from abacavir-mp |
| 05/16/2002 | WO2002038742A2 Dipeptidylpeptidases and methods of use |
| 05/16/2002 | WO2002038738A2 Chimeric molecules to modulate gene expression |
| 05/16/2002 | WO2002038730A2 Novel human potassium channel beta subunit |
| 05/16/2002 | WO2002038726A2 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/16/2002 | WO2002038646A2 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 05/16/2002 | WO2002038610A1 Process for the preparation of latent antithrombin iii |
| 05/16/2002 | WO2002038609A2 Apolipoprotein conjugates |
| 05/16/2002 | WO2002038607A2 A 'bach' g protein coupled receptor polypeptide and polynucleotide encoding this receptor |
| 05/16/2002 | WO2002038606A2 Compositions and methods relating to ovary specific genes and proteins |
| 05/16/2002 | WO2002038604A1 A new polypeptide-cicliary rootlet protein 45.98 and the polynucleotide encoding it |
| 05/16/2002 | WO2002038603A1 A novel peptide---human large protein 1225-13.87 and the polynucleotide coding this novel peptide |
| 05/16/2002 | WO2002038601A2 Foggy |
| 05/16/2002 | WO2002038600A2 C. elegans genes involved in viability and/or reproduction and uses thereof |
| 05/16/2002 | WO2002038597A2 Genomic fragment of streptococcus suis and clinical uses thereof |
| 05/16/2002 | WO2002038591A1 Fap-activated anti-tumor compounds |
| 05/16/2002 | WO2002038590A1 Fap-alpha-activated anti-tumor compounds |
| 05/16/2002 | WO2002038587A2 Haplotypes of the grm8 gene |
| 05/16/2002 | WO2002038586A2 Haplotypes of the il6 gene |
| 05/16/2002 | WO2002038187A1 Fap-activated anti-tumour prodrug |
| 05/16/2002 | WO2002038179A1 Preventives or remedies for endoplasmic reticulum stress-associated diseases |
| 05/16/2002 | WO2002038173A1 Vaccine based on a cellular penetration factor from an apicomplexan parasite |
| 05/16/2002 | WO2002038171A2 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 05/16/2002 | WO2002038170A2 Stabilized inteferon compositions |
| 05/16/2002 | WO2002038169A1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 05/16/2002 | WO2002038168A2 Use of selectin-binding active ingredients for the treatment of inflammatory and tumoral diseases |
| 05/16/2002 | WO2002038167A2 Use of factor xiii for treating hemophilia b |
| 05/16/2002 | WO2002038164A1 Combination preparation of a biological response modifier and an anticancer agent and uses thereof |
| 05/16/2002 | WO2002038162A1 MODIFIED FACTOR VIIa |